Fibrin mechanisms and functions in nervous system pathology

Molecular Interventions

Volumn 4, Issue 3, 2004, Pages 163-176

  Adams, Ryan A ^a   Passino, Melissa ^a   Sachs, Benjamin D ^a   Nuriel, Tal ^a,b   Akassoglou, Katerina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR; BLOOD CLOTTING INHIBITOR; CADHERIN; CD11B ANTIGEN; CD18 ANTIGEN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GELSOLIN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN; PROTEINASE; SOMATOMEDIN BINDING PROTEIN 3; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ALZHEIMER DISEASE; ANGIOGENESIS; BACTERIAL MENINGITIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL RUPTURE; BRAIN EDEMA; DEGENERATIVE DISEASE; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN FUNCTION; REVIEW; STROKE; SYNAPTIC POTENTIAL; VIRUS ENCEPHALITIS;

AMINO ACID SEQUENCE; ANCROD; ANIMALS; BLOOD-BRAIN BARRIER; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HOMEOSTASIS; HUMANS; INFLAMMATION; MACROPHAGES; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE REGENERATION; NERVOUS SYSTEM; NEUROGLIA; NEURONS; SIGNAL TRANSDUCTION;

EID: 3242690811     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Kandel, E.R., Schwartz J.H., and Jessell T.M., Principles of Neural Science. 3rd ed. Elsevier Press, London (1991).
2. Mukouyama, Y.S., Shin, D., Britsch, S., Taniguchi, M., and Anderson, D.J. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109, 693-705 (2002).
3. Fruttiger, M., Calver, A.R., Kruger, W.H., Mudhar, H.S., Michalovich, D., Takakura, N., Nishikawa, S., and Richardson, W.D. PDGF mediates a neuron-astrocyte interaction in the developing retina. Neuron 17, 1117-1131 (1996).
4. Honma, Y., Araki, T., Gianino, S., Bruce, A., Heuckeroth, R., Johnson, E., and Millbrandt, J. Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. Neuron 35, 267-282 (2002).
5. McCarty, J.H., Monahan-Earley, R.A., Brown, L.F. et al. Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking av integrins. Mol. Cell. Biol. 22, 7667-7677 (2002).
6. Palmer, T.D., Willhoite, A.R., and Gage, F.H. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol. 425, 479-494 (2000).
7. Louissaint, A., Jr., Rao, S., Leventhal, C., and Goldman, S.A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34, 945-960 (2002).
8. Simard, M.,Arcuino, G., Takano, T., Liu, Q.S., and Nedergaard, M. Signaling at the gliovascular interface. J. Neurosci. 23, 9254-9262 (2003).
9. Sheth, S.A., Nemoto, M., Guiou, M.,Walker, M., Pouratian, N., and Toga, A.W. Linear and nonlinear relationships between neuronal activity, oxygen metabolism, and hemodynamic responses. Neuron 42, 347-355 (2004).
10. Adams, D.L. and Horton, J.C. Shadows cast by retinal blood vessels mapped in primary visual cortex. Science 298, 572-576 (2002).
11. Lo, E.H., Dalkara, T., and Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat. Rev. Neurosci. 4, 399-415 (2003).
12. Huber, J.D., Egleton, R.D., and Davis, T.P. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24, 719-725 (2001).
13. Abbott, N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200, 629-638 (2002).
14. Wang, X. and Lo, E.H. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol. Neurobiol. 28, 229-244 (2003).
15. Langford, D. and Masliah, E. Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol. 11, 306-312 (2001).
16. Berzin, T.M., Zipser, B.D., Rafii, M.S., Kuo-Leblanc, V., Yancopoulos, G.D., Glass, D.J., Fallon, J.R., and Stopa, E.G. Agrin and microvascular damage in Alzheimer's disease. Neurobiol. Aging 21, 349-355 (2000).
17. Giri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A.M., Stern, D., Kim, K.S., Zlokovic, B., and Kalra, V.K. b-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell Physiol. 279, C1772-C1781 (2000).
18. Minagar, A. and Alexander, J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540-549 (2003).
19. Popovich, P.G., Horner, P.J., Mullin, B.B., and Stokes, B.T. A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 142, 258-275 (1996).
20. Seitz, R.J. and Wechsler, W: Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol. (Berl.) 73, 145-152 (1987).
21. Roberts, H.C., Roberts, T.P., Brasch, R.C., and Dillon, W.P. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. AJNR Am. J. Neuroradiol. 21, 891-899 (2000).
22. Kim, K.S. Pathogenesis of bacterial meningitis: From bacteraemia to neuronal injury. Nat. Rev. Neurosci. 4, 376-385 (2003).
23. Kamath, S. and Lip, G.Y. Fibrinogen: Biochemistry, epidemiology and determinants. QJM 96, 711-729 (2003).
24. Friedmann, I.,Faber-Elman, A., Yoles, E., and Schwartz, M. Injury-induced gelatinase and thrombin-like activities in regenerating and nonregenerating nervous systems. FASEB J. 13, 533-543 (1999).
25. Thomas, W.S., Mori, E., Copeland, B.R., Yu, J.Q., Morrissey, J.H., and del Zoppo, G.J. Tissue factor contributes to microvascular defects after focal cerebral ischemia. Stroke 24, 847-853 (1993).
26. Akassoglou, K. and Strickland, S. Nervous system pathologies: The fibrin perspective. Biol. Chem. 383, 37-45 (2002).
27. Esmon, C.T. Does inflammation contribute to thrombotic events? Haemostasis 30, 34-40 (2000).
28. Sidelmann, J.J., Gram, J., Jespersen, J., and Kluft, C. Fibrin clot formation and lysis: Basic mechanisms. Semin. Thromb. Hemost. 26, 605-618 (2000).
29. Senior, R.M., Skogen, W.F., Griffin, G.L., and Wilner, G.D. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J. Clin. Invest. 77, 1014-1019 (1986).
30. Spraggon, G., Everse, S.J., and Doolittle, R.F. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 389, 455-462 (1997).
31. Brown, J.H., Volkmann, N., Jun, G., Henschen-Edman, A.H., and Cohen, C. The crystal structure of modified bovine fibrinogen. Proc. Natl. Acad. Sci. U.S.A. 97, 85-90 (2000).
32. Yang, Z., Mochalkin, I., Veerapandian, L., Riley, M., and Doolittle, R.F. Crystal structure of native chicken fibrinogen at 5.5-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 97, 3907-3912 (2000).
33. Yang, Z., Mochalkin, I., and Doolittle, R.F. A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. Proc. Natl. Acad. Sci. U.S.A. 97, 14156-14161 (2000).
34. Lijnen, H.R. Elements of the fibrinolytic system. Ann. N.Y. Acad. Sci. 936, 226-236 (2001).
35. Gaffney, P.J. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann. N.Y. Acad. Sci. 936, 594-610 (2001).
36. Lowe, G.D. and Rumley, A. Fibrinogen and its degradation products as thrombotic risk factors. Ann. N.Y. Acad. Sci. 936, 560-565 (2001).
37. Degen, J.L., Drew, A.F., Palumbo, J.S., Kombrinck, K.W., Bezerra, J.A., Danton, M.J., Holmback, K., and Suh, T.T. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann. N.Y. Acad. Sci. 936, 276-290 (2001).
38. Bugge, T.H., Kombrinck, K.W., Flick, M.J., Daugherty, C.C., Danton, M.J., and Degen, J.L. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709-719 (1996).
39. Phillips, D.R., Charo, I.F., Parise, L.V., and Fitzgerald, L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71, 831-843 (1988).
40. Ugarova, T.P. and Yakubenko, V.P. Recognition of fibrinogen by leukocyte integrins. Ann. N.Y. Acad. Sci. 936, 368-385 (2001).
41. 2 integrin clustering or activation in the control of apoptosis via regulation of Akt and ERK survival mechanisms. J. Cell Biol. 151, 1305-1320 (2000).
42. Perez, R.L., Ritzenthaler, J.D., and Roman, J. Transcriptional regulation of the interleukin-1β promoter via fibrinogen engagement of the CD18 integrin receptor. Am. J. Respir. Cell Mol. Biol. 20, 1059-1066 (1999).
43. Sans, E., Delachanal, E., and Duperray, A. Analysis of the roles of ICAM-1 in neutrophil transmigration using a reconstituted mammalian cell expression model: Implication of ICAM-1 cytoplasmic domain and Rho-dependent signaling pathway. J. Immunol. 166, 544-551 (2001).
44. Tsakadze, N.L., Zhao, Z., and D'Souza, S.E. Interactions of intercellular adhesion molecule-1 with fibrinogen. Trends Cardiovasc. Med. 12, 101-108 (2002).
45. Pluskota, E. and D'Souza, S.E. Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival. Eur. J. Biochem. 267, 4693-4704 (2000).
46. Martinez, J., Ferber, A., Bach, T.L., and Yaen, C.H. Interaction of fibrin with VE-cadherin. Ann. N. Y. Acad. Sci. 936, 386-405 (2001).
47. Engvall, E., Ruoslahti, E., and Miller, E.J. Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J. Exp. Med. 147, 1584-1595 (1978).
48. Grinnell, F., Feld, M. and Minter, D. Fibroblast adhesion to fibrinogen and fibrin substrata: Requirement for cold-insoluble globulin (plasma fibronectin). Cell 19, 517-525 (1980).
49. Smith, D.B., Janmey, P.A., Herbert, T.J., and Lind, S.E. Quantitative measurement of plasma gelsolin and its incorporation into fibrin clots. J. Lab. Clin. Med. 110, 189-195 (1987).
50. Campbell, P.G., Durham, S.K., Hayes, J.D., Suwanichkul, A., and Powell, D.R. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J. Biol. Chem. 274, 30215-30221 (1999).
51. Sahni, A., Odrljin, T., and Francis, C.W. Binding of basic fibroblast growth factor to fibrinogen and fibrin. J. Biol. Chem. 273, 7554-7559 (1998).
52. Sahni, A., Sporn, L.A., and Francis, C.W. Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J. Biol. Chem. 274, 14936-14941 (1999).
53. Sahni, A. and Francis, C.W. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 96, 3772-3778 (2000).
54. Morgenstern, E., Gnad, U., Preissner, K.T., Dierichs, R., Belleli, A., Chestukhin, A., Schvartz, I., and Shaltiel, S. Localization of protein kinase A and vitronectin in resting platelets and their translocation onto fibrin fibers during clot formation. Eur. J. Cell Biol. 80, 87-98 (2001).
55. Ponnuraj, K., Bowden, M.G., Davis, S., Gurusiddappa, S., Moore, D., Choe, D., Xu, Y., Hook, M, and Narayana, S.V. A "dock, lock, and latch" structural model for a staphylococcal adhesin binding to fibrinogen. Cell 115, 217-228 (2003).
56. Ringdahl, U., Svensson, H.G., Kotarsky, H., Gustafsson, M., Weineisen, M., and Sjobring, U. A role for the fibrinogen-binding regions of streptococcal M proteins in phagocytosis resistance. Mol. Microbiol. 37, 1318-1326 (2000).
57. Horner, P.J. and Gage, F.H. Regenerating the damaged central nervous system. Nature 407, 963-970 (2000).
58. Silver, J. and Miller, J.H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146-156 (2004).
59. Jessen, K.R. and Mirsky, R. Schwann cells and their precursors emerge as major regulators of nerve development. Trends Neurosci. 22, 402-410 (1999).
60. Jessen, K.R. and Mirsky, R. Developmental regulation in the Schwann cell lineage. Adv. Exp. Med. Biol. 468, 3-12 (1999).
61. Chen Z.L., and Strickland, S. Laminin g1 is critical for Schwann cell differentiation, axon myelination, and regeneration in the peripheral nerve. J. Cell Biol. 163, 889-899 (2003).
62. Anton, E.S., Sandrock, A.W., Jr., and Matthew, W.D. Merosin promotes neurite growth and Schwann cell migration in vitro and nerve regeneration in vivo: Evidence using an antibody to merosin, ARM-1. Dev. Biol. 164, 133-146 (1994).
63. Fernandez-Valle, C., Gwynn, L., Wood, P.M., Carbonetto, S., and Bunge, M.B. Anti-β1 integrin antibody inhibits Schwann cell myelination. J. Neurobiol. 25, 1207-1226 (1994).
64. Feltri, M.L., Porta, D.G., Previtali, S.C. et al. Conditional disruption of b1 integrin in Schwann cells impedes interactions with axons. J. Cell Biol. 156, 199-210 (2002).
65. Akassoglou, K., Kombrinck, K.W., Degen, J.L., and Strickland, S. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J. Cell Biol. 149, 1157-1166 (2000).
66. Akassoglou, K., Yu, W.-M., Akpinar, P., and Strickland, S. Fibrin inhibits peripheral nerve regeneration by arresting Schwann cell differentiation. Neuron 33, 861-875 (2002).
67. Salles, F.J., Schechter, N., and Strickland, S. A plasminogen activator is induced during goldfish optic nerve regeneration. EMBO J. 9, 2471-2477 (1990).
68. Siconolfi, L.B. and Seeds, N.W. Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J. Neurosci. 21, 4348-4355 (2001).
69. Suh, T.T., Holmback, K., Jensen, N.J., Daugherty, C.C., Small, K., Simon, D.I., Potter, S., and Degen, J.L. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9, 2020-2033 (1995).
70. Akassoglou, K., Akpinar, P., Murray, S., and Strickland, S. Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice. Neurosci. Lett. 338, 185-188 (2003).
71. Kioussi, C. and Gruss, P. Making of a Schwann. Trends Genet. 12, 84-86 (1996).
72. Chernousov, M.A. and Carey, D.J. Schwann cell extracellular matrix molecules and their receptors. Histol. Histopathol. 15, 593-601 (2000).
73. Milner, R., Wilby, M., Nishimura, S., Boylen, K., Edwards, G., Fawcett, J., Streuli, C., Pytela, R., and ffrench-Constant, C. Division of labor of Schwann cell integrins during migration on peripheral nerve extracellular matrix ligands. Dev. Biol. 185, 215-228 (1997).
74. 8 integrin is a Schwann cell receptor for fibrin. Exp. Cell Res. 291, 514-524 (2003).
75. Lassmann, H., Bruck, W., and Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 7, 115-121. (2001).
76. Kermode, A.G., Thompson, A.J., Tofts, P., MacManus, D.G., Kendall, B.E., Kingsley, D.P., Moseley, I.F., Rudge, P., and McDonald, W.I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113, 1477-1489 (1990).
77. Rindfleisch, E. Histologisches detail zu der grauen degeneration von gehirn und ruckenmark. Archives of Pathological Anatomy and Physiology 26, 474-483 (1863).
78. Claudio, L., Raine, C.S., and Brosnan, C.F. Evidence of persistent blood-brain barrier abnormalities in chronic- progressive multiple sclerosis. Acta Neuropathol. 90, 228-238 (1995).
79. Wakefield, A.J., More, L.J., Difford, J., and McLaughlin, J.E. Immunohistochemical study of vascular injury in acute multiple sclerosis. J. Clin. Pathol. 47, 129-133 (1994).
80. Gay, F.W., Drye, T.J., Dick, G.W., and Esiri, M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120, 1461-1483 (1997).
81. Gveric, D., Hanemaaijer, R., Newcombe, J., van Lent, N.A., Sier, C.F., and Cuzner, M.L. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain 124, 1978-1988 (2001).
82. Kirk, J., Plumb, J., Mirakhur, M., and McQuaid, S. Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 201, 319-327 (2003).
83. Gingrich, M.B. and Traynelis, S.F. Serine proteases and brain damage - is there a link? Trends Neurosci. 23, 399-407 (2000).
84. Tsirka, S.E. Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 3, 222-225 (2002).
85. Pawlak, R. and Strickland, S. Tissue plasminogen activator and seizures: A clot-buster's secret life. J. Clin. Invest. 109, 1529-1531 (2002).
86. Melchor, J.P., Pawlak, R., Chen, Z., and Strickland, S. The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease. J. Mol. Neurosci. 20, 287-289 (2003).
87. Benchenane, K., Lopez-Atalaya, J.P., Fernandez-Monreal, M., Touzani, O., and Vivien, D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci. 27, 155-160 (2004).
88. Lo, E.H., Broderick, J.P. and Moskowitz, M.A. tPA and proteolysis in the neurovascular unit. Stroke 35, 354-356 (2004).
89. Akenami, F.O., Siren, V., Koskiniemi, M., Siimes, M.A., Teravainen, H., and Vaheri, A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J. Clin. Pathol. 49, 577-580 (1996).
90. Teesalu, T., Kulla, A., Asser, T., Koskiniemi, M., and Vaheri, A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem. Soc. Trans. 30, 183-189 (2002).
91. Akenami, F.O., Siren, V., Wessman, M., Koskiniemi, M., and Vaheri, A. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J. Neurol. Sci. 165, 71-76 (1999).
92. Gveric, D., Herrera, B., Petzold, A., Lawrence, D.A., and Cuzner, M.L. Impaired fibrinolysis in multiple sclerosis: A role for tissue plasminogen activator inhibitors. Brain. 126, 1-9 (2003).
93. Onodera, H., Nakashima, I., Fujihara, K., Nagata, T., and Itoyama, Y. Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis. Tohoku J. Exp. Med. 189, 259-265 (1999).
94. Akenami, F.O., Koskiniemi, M., Farkkila, M., and Vaheri, A. Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease. J Clin. Pathol. 50, 157-160 (1997).
95. Sobel, R.A., Schneeberger, E.E., and Colvin, R.B. The immunopathology of acute experimental allergic encephalomyelitis. V. A light microscopic and ultrastructural immunohistochemical analysis of fibronectin and fibrinogen. Am. J. Pathol. 131, 547-558 (1988).
96. Ackermann, H.P., Ulrich, J., and Heitz, P.U. Experimental allergic encephalomyelitis. Exudate and cellular infiltrates in the spinal cord of Lewis rats. Acta Neuropathol. (Berl) 54, 149-152 (1981).
97. Raine, C.S., Barnett, L.B., Brown, A., Behar, T., and McFarlin, D.E. Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab. Invest. 43, 150-157 (1980).
98. Paterson, P.Y. Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35, 2428-2434 (1976).
99. Inoue, A., Koh, C.S., Shimada, K., Yanagisawa, N., and Yoshimura, K. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J. Neuroimmunol. 71, 131-137 (1996).
100. Teesalu, T., Hinkkanen, A.E. and Vaheri, A. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am. J. Pathol. 159, 2227-2237 (2001).
101. Lu, W., Bhasin, M., and Tsirka, S.E. Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J. Neurosci. 22, 10781-10789 (2002).
102. Smith, M.E. and L.A. Amaducci, Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis. Neurochem. Res. 7, 541-554 (1982).
103. Brosnan, C.F., Cammer, W., Norton, W.T., and Bloom, B.R. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285, 235-237 (1980).
104. Koh, C.S., Kwaan, H.C., and Paterson, P.Y. Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis. J. Neuroimmunol. 28, 189-200 (1990).
105. Paterson, P.Y., Gausas, J., Koh, C.S., and Kwaan, H.C. The clotting system: Gatekeeper of cerebrovascular permeability and monitor of clinical manifestations of neuroautoimmune disease. Trans. Am. Clin. Climatol. Assoc. 97, 149-157 (1985).
106. Paterson, P.Y., Koh, C.S., and Kwaan, H.C. Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed. Proc. 46, 91-96 (1987).
107. Koh, C. Role of the clotting-fibrinolysis system in the pathogenesis of experimental allergic encephalomyelitis in Neuroimmunological Diseases(A. Igata ed) pp 169-174 (1988).
108. Hirsch, H.E., Blanco, C.E., and Parks, M.E. Fibrinolytic activity of plaques and white matter in multiple sclerosis. J. Neuropathol. Exp. Neurol. 40, 271-280 (1981).
109. Owens, T., Wekerle, H., and Antel, J. Genetic models for CNS inflammation. Nat. Med. 7, 161-166 (2001).
110. Becher, B., Prat, A., and Antel, J.P. Brain-immune connection: immunoregulatory properties of CNS-resident cells. Glia 29, 293-304 (2000).
111. Pouly, S. and Antel, J.P. Multiple sclerosis and central nervous system demyelination. J. Autoimmun. 13, 297-306 (1999).
112. Akassoglou, K., Bauer, J., Kassiotis, G., Pasparakis, M., Lassmann, H., Kollias, G., and Probert, L. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: Models for multiple sclerosis with primary oligodendrogliopathy. Am. J. Pathol. 153, 801-813 (1998).
113. Probert, L., Eugster, H.P., Akassoglou, K., Bauer, J., Frei, K., Lassmann, H., and Fontana, A. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 123, 2005-2019 (2000).
114. Lucchinetti, C.F., Bruck, W., Rodriguez, M., and Lassmann, H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259-274 (1996).
115. Barnett, M.H. and Prineas, J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458-468 (2004).
116. Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mork, S., and Bo, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
117. Probert, L. and Akassoglou, K. Glial expression of tumor necrosis factor in transgenic animals: How do these models reflect the "normal situation"? Glia 36, 212-219 (2001).
118. Akassoglou, K., Adams, R.A., Bauer, J., Mercado, P., Tseveleki, V., Lassmann, H., Probert, L., and Strickland, S. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. U S A 101, 6698-6703 (2004).
119. Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M., and Lassmann, H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
120. Altieri, D.C. Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb. Haemost. 82, 781-786 (1999).
121. Perez, R.L. and Roman, J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells. Implications in pulmonary inflammation. J. Immunol. 154, 1879-1887 (1995).
122. Fan, S.T and Edgington, T.S. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J. Immunol. 150, 2972-2980 (1993).
123. Smiley, S.T, King, J.A., and Hancock, W.W. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167, 2887-2894 (2001).
124. Kornek, B. and Lassmann, H. Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. 61, 321-326 (2003).
125. Koh, C.S., Gausas, J., and Paterson, P.Y. Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J. Neuroimmunol. 47, 141-145 (1993).
126. Rebhun, J., Madorsky, J.G., and Glovsky, M.M. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann. Allergy 66, 335-338 (1991).
127. Raisman, G. Sniffing out new approaches to spinal cord repair. Nat. Med. 6, 382-383 (2000).
128. Abe, Y., Nakamura, H., Yoshino, O., Oya, T., and Kimura, T. Decreased neural damage after spinal cord injury in tPA-deficient mice. J. Neurotrauma 20, 43-57 (2003).
129. Boudaoud, L., Roussi, J., Lortat-Jacob, S., Bussel, B., Dizien, O., and Drouet, L. Endothelial fibrinolytic reactivity and the risk of deep venous thrombosis after spinal cord injury. Spinal Cord 35, 151-157 (1997).
130. Green, D. Diagnosis, prevalence, and management of thromboembolism in patients with spinal cord injury. J. Spinal Cord. Med. 26, 329-334 (2003).
131. Iadecola, C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5, 347-360 (2004).
132. Kalaria, R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N. Y. Acad. Sci. 893, 113-125 (1999).
133. Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171 (1996).
134. Merkle, D.L., Cheng, C.H., Castellino, F.J., and Chibber, B.A. Modulation of fibrin assembly and polymerization by the β -amyloid of Alzheimer's disease. Blood Coagul. Fibrinolysis, 7, 650-658 (1996).
135. Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Scheff, S., McGillis, J.P., Rydel, R.E., and Estus, S. The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20, 3937-3946 (2000).
136. Melchor, J.P., Pawlak, R., and Strickland, S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-β (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci. 23, 8867-8871 (2003).
137. Larsen, P.H., Wells, J.E., Stallcup, W.B., Opdenakker, G., and Yong, V.W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23, 11127-11135 (2003).
138. Tsirka, S.E., Gualandris, A., Amaral, D.G., and Strickland, S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340-344 (1995).
139. Wang, Y.F., Tsirka, S.E., Strickland, S., Stieg, P.E., Soriano, S.G., and Lipton, S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228-231 (1998).
140. Dijkhuizen, R.M., Asahi, M., Wu, O., Rosen, B.R., and Lo, E.H. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 33, 2100-2104 (2002).
141. Kwon, E.E. and Prineas, J.W. Blood -brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J. Neuropathol. Exp. Neurol. 53, 625-636 (1994).
142. Burkhart, W., Smith, G.F., Su, J.L., Parikh, I., and LeVine, H. Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of Agkistrodon rhodostoma. FEBS Lett. 297, 297-301 (1992).
143. Bell, W.R., Shapiro, S.S., Martinez, J., and Nossel, H.L. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man. J. Lab. Clin. Med. 91, 592-604 (1978).
144. Brenner, K.A., Corbett, S.A., and Schwarzbauer, J.E. Regulation of fibronectin matrix assembly by activated Ras in transformed cells. Oncogene 19, 3156-3163 (2000).
145. Morgan, L., Jessen, K.R., and Mirsky, R. The effects of cAMP on differentiation of cultured Schwann cells: progression from an early phenotype (04+) to a myelin phenotype (P0+, GFAP-, N-CAM-, NGF-receptor-) depends on growth inhibition. J. Cell Biol. 112, 457-467 (1991).
146. Poser, C.M., An Atlas of Multiple Sclerosis. The Parthenon Publishing Group Inc, New York, NY, 1998: p.60.
147. 1 on endothelial cells. J. Biol. Chem. 272, 5360-5366 (1997).
148. Rubel, C., Gomez, S., Fernandez, G.C., Isturiz, M.A., Caamano, J., and Palermo, M.S. Fibrinogen-CD11b/CD18 interaction activates the NF-κB pathway and delays apoptosis in human neutrophils. Eur. J. Immunol. 33, 1429-1438 (2003).
149. Rubel, C., Fernandez, G.C., Rosa, F.A., Gomez, S., Bompadre, M.B., Coso, O.A., Isturiz, M.A., and Palermo, M.S. Soluble fibrinogen modulates neutrophil functionality through the activation of an extracellular signal-regulated kinase-dependent pathway. J. Immunol. 168, 3527-3535 (2002).
150. Altieri, D.C., Bader, R., Mannucci, P.M., and Edgington, T.S. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J. Cell Biol. 107, 1893-1900 (1988).
151. 2-integrin CD11b/CD18. Blood 88, 146-157 (1996).
152. Forsyth, C.B, Solovjov, D.A., Ugarova, T.P., and Plow, E.F. Integrin aMb2-mediated cell migration to fibrinogen and its recognition peptides. J. Exp. Med. 193, 1123-1133 (2001).
153. Zauli, G., Bassini, A., Vitale, M., Gibellini, D., Celeghini, C., Caramelli, E., Pierpaoli, S., Guidotti, L., and Capitani, S. Thrombopoietin enhances the aIIbb3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 89, 883-895 (1997).
154. Cheresh, D.A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. U.S.A. 84, 6471-6475 (1987).
155. Gailit, J., Clarke, C., Newman, D., Tonnesen, M.G., Mosesson, M.W., and Clark, R.A. Human fibroblasts bind directly to fibrinogen at RGD sites through integrin avb3. Exp. Cell Res. 232, 118-126 (1997).
156. Sans, E., Delachanal, E., and Duperray, A. Analysis of the roles of ICAM-1 in neutrophil transmigration using a reconstituted mammalian cell expression model: Implication of ICAM-1 cytoplasmic domain and Rho-dependent signaling pathway. J. Immunol. 166, 544-551 (2001).
157. Altieri, D.C., Duperray, A., Plescia, J., Thornton, G.B., and Languino, L.R. Structural recognition of a novel fibrinogen gamma chain sequence (117-133) by intercellular adhesion molecule-1 mediates leukocyte-endothelium interaction. J. Biol. Chem. 270, 696-699 (1995).
158. Duperray, A., Languino, L.R., Plescia, J., McDowall, A., Hogg, N., Craig, A.G., Berendt, A.R., and Altieri, D.C. Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J. Biol. Chem. 272, 435-441 (1997).
159. Languino, L.R., Plescia, J., Duperray, A., Brian, A.A., Plow, E.F., Geltosky, J.E., and Altieri, D.C. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73, 1423-1434 (1993).
160. Languino, L.R., Duperray, A., Joganic, K.J., Fornaro, M., Thornton, G.B., and Altieri, D.C. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1-fibrinogen recognition. Proc. Natl. Acad. Sci. U.S.A. 92, 1505-1509 (1995).
161. Odrljin, T.M., Francis, C.W., Sporn, L.A., Bunce, L.A., Marder, V.J., and Simpson-Haidaris, P.J. Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16, 1544-1551 (1996).
162. Sporn, L.A., Bunce, L.A., and Francis, C.W. Cell proliferation on fibrin: Modulation by fibrinopeptide cleavage. Blood 86, 1802-1810 (1995).
163. Chalupowicz, D.G., Chowdhury, Z.A., Bach, T.L., Barsigian, C., and Martinez, J. Fibrin II induces endothelial cell capillary tube formation. J. Cell Biol. 130, 207-215 (1995).
164. Bach, T.L., Barsigian, C., Yaen, C.H., and Martinez, J. Endothelial cell VE-cadherin functions as a receptor for the b15-42 sequence of fibrin. J. Biol. Chem. 273, 30719-30728 (1998).
165. Liu, C.Y., Nossel, H.L., and Kaplan, K.L. The binding of thrombin by fibrin. J. Biol. Chem. 254, 10421-10425 (1979).
166. Levin, E.G. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc. Natl. Acad. Sci. U.S.A. 80, 6804-6808 (1983).